Drugs / Lu AG22515
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06557850 | Sep 2024 → Mar 2026 overdue | endocrine exophthalmos | H. Lundbeck A/S | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05136053 | Mar 2022 → Aug 2023 | — | H. Lundbeck A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lu AG22515 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06557850 ↗ |
| Route | Intravenous | “Participants will receive a single intravenous (IV) infusion of Lu AG22515.” NCT05136053 ↗ |